{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}],"title":"Performance Status 0"},{"measurements":[{"groupId":"OG000","value":"23"}],"title":"Performance Status 1"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Performance Status 2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.","groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"OG000","title":"Bevacizumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Performance Status","type":"SECONDARY","unitOfMeasure":"Participants"}